Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine for Suicidal Ideation in Major Depressive Disorder
IRCT20190317043079N4Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ketamine in major depressive disorder (MDD) and suicidal ideation, sponsored by Babol University of Medical Sciences. Primary endpoint: Change in suicidal ideation. Started Apr 2023; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)suicidal ideation
Beyond the preview
Go deeper on IRCT20190317043079N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190317043079N4.